Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicyJoin the MICROB-PREDICT Consensus Conference at EASL Congress
We cordially invite hepatology & microbiome colleagues who attend EASL Congress 2026 in Barcelona to join the MICROB-PREDICT Consensus Conference on Wednesday, 27 May (15:30 – 18:30 h, Jansen Room). Chaired by Prof Jonel Trebicka and Prof Minneke Coenraad, the session brings together leading researchers to discuss microbiome-based mechanisms and biomarkers for improved patient stratification and therapeutic response prediction in decompensated cirrhosis and ACLF. The Consensus Conference Programme combines expert presentations and structured discussions to identify key findings, knowledge gaps, and future research priorities in this rapidly evolving field. The meeting is face-to-face (not hybrid), and participants need to be registered for EASL Congress to attend the Consensus Conference. We look forward to seeing you there!
More newsMICROB-PREDICT Networking Session on Saturday, 30 May 2026, at EASL Congress
Join us for The MICROB-PREDICT Networking Session about "Highlights from the MICROB-PREDICT Consensus Conference" on Saturday, 30 May, 11:45–12:15 (CEST) at Track Hub 6 – Cirrhosis & Complications. The networking session addresses all ACLF and microbiome experts and enthusiasts to discuss how microbiome-driven discoveries are advancing our understanding of cirrhosis and ACLF, with a focus on disease mechanisms, biomarkers, and therapeutic response. Jonel Trebicka (UKM, Germany) will present insights into mechanisms and biomarkers of progression in decompensated cirrhosis and ACLF, while Minneke Coenraad (LUMC, The Netherlands) will speak about areas of consensus and disagreement regarding the mechanisms and biomarkers of therapeutic response to Albumin, Rifaximin, and Terlipressin. We warmly invite you to join the event & discussion!
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news